Reprimo
Reprimo (RPRM), is a gene located at human chromosome 2q23 whose expression in conjunction with p53, along with other genes which are p53-induced, is associated with the arrest of the cell cycle at the G2 phase.{{Cite journal|title = Reprimo, a New Candidate Mediator of the p53-mediated Cell Cycle Arrest at the G2 Phase|journal = Journal of Biological Chemistry|date = 2000-07-28|issn = 0021-9258|pages = 22627–22630|volume = 275|issue = 30|doi = 10.1074/jbc.C000235200|pmid = 10930422|first1 = Rieko|last1 = Ohki|first2 = Jiro|last2 = Nemoto|first3 = Hideki|last3 = Murasawa|first4 = Eri|last4 = Oda|first5 = Johji|last5 = Inazawa|first6 = Nobuyuki|last6 = Tanaka|first7 = Tadatsugu|last7 = Taniguchi|doi-access = free}}{{Cite journal|title = The p53 circuit board|journal = Biochimica et Biophysica Acta (BBA) - Reviews on Cancer|date = 2012-04-01|pmc = 3307870|pmid = 22333261|pages = 229–244|volume = 1825|issue = 2|doi = 10.1016/j.bbcan.2012.01.004|first1 = Kelly D.|last1 = Sullivan|first2 = Corrie L.|last2 = Gallant-Behm|first3 = Ryan E.|last3 = Henry|first4 = Jean-Luc|last4 = Fraikin|first5 = Joaquín M.|last5 = Espinosa}} Reprimo's protein product is a highly glycosylated polypeptide which, upon its expression, is localized to the cytoplasm where it is primarily active. As the expression of reprimo is controlled by p53, which is in turn controlled by a wide array of convergent signal pathways pertaining to DNA damage or nutrient depravity, its presence is expected within cells which would cause damage should they be freely allowed to replicate. Pursuant to this, reprimo
Identification of this gene's repression via methylation to its upstream promoter region{{Cite journal|title = Aberrant methylation of Reprimo correlates with genetic instability and predicts poor prognosis in pancreatic ductal adenocarcinoma|journal = Cancer|date = 2006-07-15|issn = 1097-0142|pages = 251–257|volume = 107|issue = 2|doi = 10.1002/cncr.21977|first1 = Norihiro|last1 = Sato|first2 = Noriyoshi|last2 = Fukushima|first3 = Hiroyuki|last3 = Matsubayashi|first4 = Christine A.|last4 = Iacobuzio-Donahue|first5 = Charles J.|last5 = Yeo|first6 = Michael|last6 = Goggins|pmid=16752411|s2cid = 27475903|doi-access = }} within various types of cancerous tissue have been used to suggest a connection to the formation of said cancer.{{needs source|date=October 2024}} These methylation events commonly cause aberrant DNA splicing which may cause one of many potential errors within the resulting mutant reprimo that ultimately undermine its ability to be expressed, have its intended effects, or to accumulate in sufficient quantities to produce the expected arrest reaction. The variability of these outcomes is owed to the large probability space for these point mutations. There is also research to suggest that this gene's expression status within specific tissues may be useful information for the diagnosis or prognosis of certain types of cancer.
Utility in cancer detection and prognosis
In those whom have already been diagnosed with primary pancreatic cancer, there is a correlative relationship to suggest there will be a much worse prognosis when said tissues were found to contain these methylations to reprimo
In terms of early detection, the methylation status of reprimo in esophageal and gastric tissues have had some success in predicting the development of cancer.{{Cite journal|title = Reprimo Methylation Is a Potential Biomarker of Barrett's-Associated Esophageal Neoplastic Progression|url = http://clincancerres.aacrjournals.org/content/12/22/6637|journal = Clinical Cancer Research|date = 2006-11-15|issn = 1078-0432|pmid = 17121882|pages = 6637–6642|volume = 12|issue = 22|doi = 10.1158/1078-0432.CCR-06-1781|first1 = James P.|last1 = Hamilton|first2 = Fumiaki|last2 = Sato|first3 = Zhe|last3 = Jin|first4 = Bruce D.|last4 = Greenwald|first5 = Tetsuo|last5 = Ito|first6 = Yuriko|last6 = Mori|first7 = Bogdan C.|last7 = Paun|first8 = Takatsugu|last8 = Kan|first9 = Yulan|last9 = Cheng|doi-access = free}}{{Cite journal|title = Reprimo as a Potential Biomarker for Early Detection in Gastric Cancer|url = http://clincancerres.aacrjournals.org/content/14/19/6264|journal = Clinical Cancer Research|date = 2008-10-01|issn = 1078-0432|pmid = 18829507|pages = 6264–6269|volume = 14|issue = 19|doi = 10.1158/1078-0432.CCR-07-4522|first1 = Carolina|last1 = Bernal|first2 = Francisco|last2 = Aguayo|first3 = Cynthia|last3 = Villarroel|first4 = Macarena|last4 = Vargas|first5 = Ignacio|last5 = Díaz|first6 = Francisco J.|last6 = Ossandon|first7 = Eudocia|last7 = Santibáñez|first8 = Mariana|last8 = Palma|first9 = Edmundo|last9 = Aravena|doi-access = free|url-access = subscription|hdl = 10533/141984|hdl-access = free}} In the case of gastric cancer, detection methods include sampling of blood plasma.{{needs source|date=October 2024}}
References
{{reflist}}